Welichem Successfully Completes Two Phase Ii Clinical Trials of Wbi-1001 Cream in Patients With Psoriasis and Atopic Dermatitis

VANCOUVER, Feb. 2 /CNW/ - Welichem Biotech is pleased to announce the successful completion of two Phase II clinical trials with WBI-1001 on psoriasis and atopic dermatitis. Both studies were 12-week, double-blinded, placebo-controlled clinical trials conducted under the regulatory guidelines of Health Canada. Based on analysis of the data, both the primary and secondary efficacy and safety endpoints were met in both studies.

ON BEHALF OF THE BOARD

Dr. John M. Webster, Chairman of the Board

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune disease and cancer.

For further information:

Liren Tang, PhD. Chief Executive Officer. Tel.: (604) 432-1703, E-mail: lirentang@welichem.com

Posted: February 2011

View comments

Hide
(web4)